Kestra Medical Technologies, Ltd. Common Stock (KMTS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.71B
Last updated: Nov 17, 2026 at 11:05 AM ET
Kestra Medical Technologies, Ltd. Common Stock (KMTS) Financials: Revenue, Profit and Cash Flow
Kestra Medical Technologies, Ltd. Common Stock reported revenue of $95.13M for the fiscal year ended Apr 30, 2026, up 59.0% from the year before. That year, net income was -$131.61M with a net margin of -138.4%, operating cash flow was -$81.70M and free cash flow was -$116.59M. The quarter ended Jul 31, 2026 had revenue of $30.97M and net income of -$44.09M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Apr 2026 | $95.13M | +59.0% | 51.4% | -141.6% | -138.4% |
| Apr 2025 | $59.81M | +115.1% | 40.5% | -177.8% | -190.3% |
| Apr 2024 | $27.81M | +264.5% | 1.3% | -305.8% | -338.4% |
| Apr 2023 | $7.63M | N/A | -139.6% | -1054.0% | -1104.0% |
| Apr 2021 | $0 | N/A | N/A | N/A | N/A |
| Apr 2020 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Apr 2026, the net loss widened from the year before. In the quarter ended Jul 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
| Revenue | $95.13M | $59.81M | $27.81M | $7.63M | $0 | $0 |
| Cost of revenue | $46.26M | $35.60M | $27.45M | $18.28M | N/A | N/A |
| Gross profit | $48.86M | $24.21M | $362.00K | -$10.65M | N/A | N/A |
| Research and development | $19.48M | $15.65M | $15.49M | $15.76M | $18.81M | $22.80M |
| Operating income | -$134.74M | -$106.38M | -$85.06M | -$80.42M | -$32.71M | -$29.32M |
| Net income | -$131.61M | -$113.81M | -$94.12M | -$84.24M | -$34.10M | -$29.47M |
| EBITDA | -$121.65M | -$99.78M | -$75.70M | -$73.74M | -$32.33M | -$28.84M |
Quarterly
| Line item | Jul 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.97M | $24.55M | $22.57M | $19.37M | $2.79M | $15.09M | $14.71M | $12.78M | $10.05M | $8.28M | $14.71M | $12.78M |
| Gross profit | $17.50M | $12.91M | $11.42M | $8.85M | -$2.61M | $6.55M | $5.83M | $4.20M | $1.40M | $880.00K | $5.83M | $4.20M |
| Operating income | -$37.66M | -$34.77M | -$31.75M | -$28.88M | -$25.14M | -$20.60M | -$19.13M | -$18.43M | -$20.35M | -$19.95M | -$19.13M | -$18.43M |
| Net income | -$44.09M | -$34.17M | -$32.78M | -$25.83M | -$33.69M | -$21.51M | -$20.37M | -$19.88M | -$22.28M | -$21.62M | -$20.37M | -$19.88M |
Balance Sheet
As of Apr 2026, cash and equivalents exceeded long-term debt of $42.65M by $57.06M.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
| Total assets | $358.46M | $295.74M | $45.95M | $38.66M | $30.52M | $7.87M |
| Current assets | $222.36M | $255.33M | $14.91M | $18.42M | $26.20M | $6.17M |
| Cash and equivalents | $99.71M | $237.59M | $8.25M | $14.81M | $24.34M | $5.76M |
| Total liabilities | $98.81M | $90.34M | $78.22M | $156.23M | $28.76M | $4.02M |
| Short-term debt | N/A | $374.00K | N/A | $21.81M | $1.06M | $452.00K |
| Long-term debt | $42.65M | $41.10M | $42.54M | $17.32M | $20.24M | N/A |
| Shareholder equity | $259.66M | $205.41M | $0 | -$117.58M | $1.77M | $3.86M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Apr 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $347.36M | $358.46M | $379.34M | $246.70M | $266.30M | $295.74M | $108.00M | $246.70M | $266.30M | $45.95M | N/A | $38.66M |
| Total liabilities | $125.00M | $98.81M | $91.35M | $82.62M | $82.14M | $90.34M | $85.38M | $82.62M | $82.14M | $255.33M | N/A | $156.23M |
| Cash and equivalents | $68.56M | $99.71M | $291.32M | $175.42M | $201.21M | $237.59M | $54.35M | $175.42M | $201.21M | $8.25M | N/A | $14.81M |
| Shareholder equity | $222.36M | $259.66M | $287.99M | $164.08M | $184.16M | $205.41M | -$274.05M | $164.08M | $184.16M | -$209.38M | N/A | -$117.58M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Apr 2026.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$81.70M | -$77.61M | -$72.23M | -$69.64M | -$29.89M | -$30.29M |
| Capital expenditures | $34.89M | $22.94M | $12.23M | $15.46M | $336.00K | $232.00K |
| Free cash flow | -$116.59M | -$100.54M | -$84.46M | -$85.10M | -$30.23M | -$30.52M |
| Dividends paid | N/A | $1.65M | $799.00K | $671.00K | $187.00K | $183.00K |
| Share repurchases | $2.47M | $3.22M | $0 | N/A | N/A | N/A |
| Investing cash flow | -$203.28M | -$23.31M | -$12.23M | -$15.46M | -$334.00K | -$232.00K |
| Financing cash flow | $147.09M | $330.26M | $77.72M | $96.11M | $48.81M | $30.24M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.30M | -$18.72M | -$18.37M | -$18.34M | -$26.27M | -$24.06M | -$8.94M | -$18.06M | -$17.50M | -$14.95M | -$15.80M | -$18.06M |
| Capital expenditures | $8.34M | $9.66M | $9.80M | $7.26M | $8.17M | $7.39M | $116.00K | $4.45M | $7.04M | $4.11M | $4.97M | $4.45M |
| Free cash flow | -$40.63M | -$28.38M | -$28.16M | -$25.61M | -$34.44M | -$31.45M | -$9.05M | -$22.50M | -$24.54M | -$19.06M | -$20.76M | -$22.50M |
Frequently Asked Questions About KMTS
What is Kestra Medical Technologies, Ltd. Common Stock's annual revenue?
Kestra Medical Technologies, Ltd. Common Stock reported revenue of $95.13M for the fiscal year ended Apr 30, 2026.
How fast is Kestra Medical Technologies, Ltd. Common Stock's revenue growing?
Revenue was up 59.0% for the fiscal year ended Apr 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 131.9%.
Is Kestra Medical Technologies, Ltd. Common Stock profitable?
No. Kestra Medical Technologies, Ltd. Common Stock reported net income of -$131.61M for the fiscal year ended Apr 30, 2026, with a net margin of -138.4%.
How much free cash flow does KMTS generate?
For the fiscal year ended Apr 30, 2026, operating cash flow of -$81.70M minus capital expenditures of $34.89M produced free cash flow of -$116.59M.
How much debt does Kestra Medical Technologies, Ltd. Common Stock have?
The balance sheet dated Apr 30, 2026 reported long-term debt of $42.65M and cash and equivalents of $99.71M.
KMTS pages: Overview, Forecast, Financials, Competitors